

# PKD in the *pcy* Mouse

## Evaluate your compounds in a human disease relevant model

The *pcy* mouse develops renal disease associated with a gene that causes human PKD, providing a translatable rodent model closely mirroring human disease development.

Confidently evaluate novel compound efficacy in a model thoroughly characterized for disease progression and treatment response. The *pcy* (CD-1-*pcy*<sup>l<sup>usm</sup></sup>) mouse model:

- Develops slowly progressing renal cystic disease
- Associated with the same gene that causes human nephronophthisis type 3
- Renal cysts initially develop in the collecting tubules, progressing to other regions of the nephron
- Male and female mice are similarly affected.

Our general study design for evaluating your novel compounds in *pcy* mice utilizes mice 5 weeks of age, with body weight and food intake recorded weekly. Test substances are administered for 15 weeks, admixed in the diet.


Endpoints commonly measured include:

- Cyst volume and fibrosis in kidney
- Kidney weight
- Serum BUN
- Concentration of the test article in the blood
- Other analyses relevant to the target may be included.

### Evaluation of Therapeutics in the *pcy* Mouse

	Mechanism	Comments
Tolvaptan	Vasopressin antagonist	Effective
Rapamycin	mTor inhibitor	Early termination

### Effect of Tolvaptan on the *pcy* Mouse



#### Contact Sales

US: +1.855.827.6968  
UK: +44 (0)870 166 6234  
[busdev@crownbio.com](mailto:busdev@crownbio.com)



#### Schedule Scientific Consultation

Request a consultation to discuss your project.  
[consultation@crownbio.com](mailto:consultation@crownbio.com)



#### DiscoverCrown

Trial translational rodent and NHP models for obesity, diabetes, renal disease, and NAFLD/NASH.  
[crownbio.com/discovercrown](http://crownbio.com/discovercrown)